Good MorningEquity markets moved higher for the 4th consecutive day despite weak labor data. The ADP data shows job growth cooling more than expected in August, suggesting a weak NFP figure on Friday. The news is taken as good news because it shows slowing in the economy, including slowing wage growth, although wage inflation is still running hot. The risk for traders is that the NFP and ADP do not often track in alignment and may provide a different perspective on Friday.
The S&P confirmed a bottom at 4,350 and is now moving higher. The index could move up to retest the recent highs and may surpass that level if this week's data is sufficiently cool. The PCE price index is the wild card; it is due on Thursday and is expected to show core consumer inflation accelerated on a YOY basis compared to last month. If that trend continues, the FOMC should be expected to continue hiking rates regardless of cooling within the labor market. Featured: URGENT WARNING About United States Bank Accounts (InvestorPlace) 
|
Markets | | |
The insurance industry faces many headwinds post-COVID normalization among them. While the headwinds continue to blow, the takeaway for investors is that insurance stocks are lightly valued, they produce cash, they pay solid dividends, margins are improving, and there are speculations of mergers a... Read the Full Story |
|
From Our PartnersFeel like you're always falling behind the market? Get access to professional investing tools for less than the cost of a Netflix subscription. Upgrade to MarketBeat All Access today for just $99.00 (normally $399.00). Get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports, and much more. | | Claim Your $300 Discount to MarketBeat All Access |
|
Stocks | | |
Remember when every car dealer on the street had no inventory and lead times extended up to a year for specific brands? The chip shortage causing supply bottlenecks in motor vehicles is taking a back seat to catch its breath and hopefully never come back into the arena.
What this means for the av... Read the Full Story |
|
Stocks | | |
Med tech has been on the skids for no fault of its own. It’s not the industry's fault that price action was driven to a frothy bubble by COVID-inspired trading outlooks or that the market has normalized. The salient point is that the med tech and med tech stocks market has normalized and pre... Read the Full Story |
|
From Our PartnersPorter Stansberry warned of the 1998 banking crisis, the Dot Com blow up, and the 2008 financial collapse…
Today, he’s issuing a different kind of warning. | | | | Full details here. |
|
Markets | | | The Russian ruble's wobble in value has exposed a crack in President Vladimir Putin's fortress economy, a vulnerability quickly plastered over by the Kremlin's economic team in a move that allowed the currency to regain its footing, at least for now.Yet the patch — an emergency interest rate increas... Read the Full Story |
|
Markets | | |
Ambarella’s (NASDAQ: AMBA) stock shed 20% following the Q2 report and guidance, but don’t read too much bearishness into the news. The company is focused on next-gen computer vision technology with low revenue levels, and it is lightly traded, making it susceptible to bad news.
The ta... Read the Full Story |
|
From Our PartnersThe events of 2022-2024 may make or break the dreams of millions of people.
But for investors who understand how these events will unfold, it will be possible for them to ride this wave of mayhem successfully …
If you have any money in the stock market … | | | | Read this urgent warning immediately |
|
Markets | | | Fund investors are keeping more of what's theirs. Fees for mutual funds and exchange-traded funds fell to a record low last year, according to Morningstar. Fund investors paid about $37 in fees for every $10,000 invested, down from $40 in 2021. Altogether, that saved them a collective $9.8 billion.W... Read the Full Story |
|
Markets | | |
Having at one point last year been down more than 75%, shares of Netflix Inc (NASDAQ: NFLX) have been having what can only be called the mother of all comebacks. They're currently up 160% from the lows twelve months ago, having recently been up as much as 200%, with many of those ga... Read the Full Story |
|
Markets | | | Swiss banking giant UBS has announced plans to save $10 billion in costs, including through 3,000 staff reductions in Switzerland as it moves ahead with “full integration” of longtime rival Credit Suisse’s domestic operations following a takeover Read the Full Story |
|
Markets | | | The U.S. economy expanded at a 2.1% annual pace from April through June, showing continued resilience in the face of higher borrowing costs for consumers and businesses, the government said in a downgrade from its initial estimate Read the Full Story |
|
Markets | | | Shawn Batey was sweating in the August sun on the 100th day of the writers strike, carrying her “IATSE Solidarity” sign on the picket line outside Netflix's New York offices, but she was glad to be there. A props assistant and documentary filmmaker, Batey is a member of the International Alliance of... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. | | View Today's Stock Pick |
|
